The Journal of Clinical and Aesthetic Dermatology
JCAD's audio platform provides interviews with leading experts in the dermatology field.Â
Tina Bhutani, MD, MAS, FAAD: Use of Spesolimab for Generalized Pustular Psoriasis
Send us Fan Mail
Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.
James Del Rosso, DO: JCAD May 2026 Issue Highlights
Send us Fan Mail
James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.
Bruce Strober, MD, PhD, FAAD: Providing Care With Risankizumab in Psoriasis
Send us Fan Mail
Bruce Strober, MD, PhD, FAAD, a clinical professor of dermatology at Yale University, discusses his extensive experience in treating patients with psoriasis. He describes his experience treating these patients with risankizumab (Skyrizi), highlighting its efficacy in treating chronic plaque psoriasis and its effectiveness for patients with comorbidities. The therapy has shown rapid improvement in high-impact areas of the body such as the scalp, palms, and soles. Dr. Strober emphasizes risankizumab's effectiveness in patients with psoriatic arthritis and those with low body surface area involvement, often making it a first-line systemic treatment for psoriasis.<...
James Del Rosso, DO: JCAD April 2026 Issue Highlights
Send us Fan Mail
James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2026 issue of JCAD.
James Del Rosso, DO, and Joseph Merola, MD, MMSc: What’s New in Cutaneous Lupus Erythematosus
Send us Fan Mail
James Del Rosso, DO, and Joseph Merola, MD, MMSc, discuss recent advances in the treatment of cutaneous lupus erythematosus (CLE). They emphasize the importance of early detection and appropriate laboratory testing to differentiate between cutaneous-only disease and systemic lupus. They highlight the late-breaking phase 2/3 AMETHYST trial (NCT05531565) data for litifilimab, which showed a significant reduction in skin disease activity in patients with CLE by Week 16.
James Del Rosso, DO, Diego Dasilva, MD, and Graham Litchman, DO, MS: Management of Severe Nail Psoriasis and Early Psoriatic Arthritis
Send us Fan Mail
James Del Rosso, DO, Diego Ruiz Dasilva, MD, and Graham Litchman, DO, MS, discuss the clinical efficacy of bimekizumab (Bimzelx) for patients with severe fingernail psoriasis and concomitant psoriatic arthritis (PsA).
They highlighted a case of a 56-year-old woman with extensive dystrophic changes across all 10 fingernails and PsA who had been misdiagnosed and treated for years with antifungals and antibiotics without improvement. After initiating bimekizumab, she achieved complete resolution of all nail and joint symptoms within 3 months.
In another case, a 63-year-old woman with nail psoriasis and symptomatic PsA...
James Del Rosso, DO, and David Cotter, MD, PhD: Clinical Management of Conjunctivitis, Erythema, and Arthralgia in AD
Send us Fan Mail
James Del Rosso, DO, and David Cotter, MD, PhD, discuss the clinical safety and efficacy of nemolizumab for patients with atopic dermatitis (AD). They highlighted a case of an 11-year-old female patient with severe AD who switched from dupilumab (Dupixent) to nemolizumab (Nemluvio). The patient achieved rapid itch reduction and resolution of conjunctivitis and facial erythema. In another case, a 22-year-old female patient with long-standing AD and joint pain switched to nemolizumab, experiencing significant improvement in itch and facial erythema within 2 months. The discussion emphasizes the importance of individualized treatment and the evolving...
James Del Rosso, DO: JCAD March 2026 Issue Highlights
Send us Fan Mail
James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the March 2026 issue of JCAD.
Ted Lain, MD, MBA: Long-Term Results of Deuruxolitinib for Alopecia Areata
Send us Fan Mail
Ted Lain, MD, a board-certified dermatologist at Sanova Dermatology in Austin, Texas, shares his extensive experience with deuruxolitinib (Leqselvi) for the treatment of patients with moderate-to-severe alopecia areata. Drawing on 5 years of long-term extension data, Dr. Lain explains that patients generally maintained hair regrowth they achieved early in treatment, with no loss of effect over time. He emphasizes that this durability is crucial, as patients are often most afraid of losing newly regrown hair.
James Del Rosso, DO: JCAD February 2026 Issue Highlights
Send us Fan Mail
James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2026 issue of JCAD.
James Del Rosso, DO, and David Cotter, MD, PhD: The Use of Gene-Expression Profile Testing for Effective Atopic Dermatitis Treatment
Send us Fan Mail
James Del Rosso, DO, and David Cotter, MD, PhD, discuss using gene expression profile testing, such as the AdvanceAD-Tx test, to provide effective treatment for patients with atopic dermatitis. AdvanceAD-Tx allows clinicians to match therapy based on patients’ immune profiles using molecular testing. Drs. Del Rosso and Cotter also review the benefits of using the test not only at baseline, but also throughout treatment in order to tailor their atopic dermatitis therapy and avoid constantly cycling through treatments.
Amy McMichael, MD: Eight-Week Outcomes With Deuruxolitinib in Alopecia Areata
Send us Fan Mail
Amy McMichael, MD, a clinical professor and chair of the Department of Dermatology at Wake Forest School of Medicine, discusses deuruxolitinib for patients with alopecia areata. She highlights its 8-week efficacy compared to placebo in clinical trials. The medication provided significant improvement in hair regrowth at the 8-mg dose, with minimal adverse events. She emphasized the need to perform standard baseline and intermittent lab tests in patients, similar to other Janus kinase inhibitors.
Graham Litchman, DO, MS: Understanding Long-Term Treatment Success in a Patient With Psoriasis
Send us Fan Mail
Graham Litchman, DO, MS, a board-certified dermatologist at Vivida Dermatology in Las Vegas, Nevada, discusses a patient case involving a 54-year-old female patient with psoriasis who did not respond well to conventional treatments or systemic steroids. Dr. Lichtman introduced her to risankizumab (Skyrizi), explaining its mechanism of action, adverse events, and dosing schedule. The patient experienced significant improvement by the 3-month mark, with most plaques disappearing. After 1 year of treatment, the patient had only a small area of plaques.
James Del Rosso, DO: JCAD January 2026 Issue Highlights
Send us Fan Mail
James Del Rosso, DO, the Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2026 issue of JCAD.
Aaron Farberg, MD: Real-World Experiences in Alopecia Areata Treatment
Send us Fan Mail
Dr. Aaron Farberg, a board-certified dermatologist and founder of Bear Dermatology in Dallas, Texas, discusses the evolving treatment landscape for alopecia areata with a focus on Janus kinase inhibitors and how he has used this type of treatment in his practice.
Arash Mostaghimi, MD, MPH, FAAD: Considerations for the Use of Deuruxolitinib in Patients with Alopecia Areata
Send us Fan Mail
Dr. Mostaghimi discusses the speed and depth of efficacy of deuruxolitinib for providing hair regrowth in patients with severe alopecia areata.
James Del Rosso, DO: JCAD November 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the November 2025 issue of JCAD.
Extended-cut Podcast—James Del Rosso, DO, and David G. Cotter, MD, PhD: Targeting the IL-31 Neuroimmune Pathway for Treating Prurigo Nodularis
Send us Fan Mail
Drs. Del Rosso and Cotter discuss advances in the molecular understanding of prurigo nodularis, which have enabled the development of targeted pharmaceuticals that treat the root of this condition.
James Del Rosso, DO: JCAD October 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the October 2025 issue of JCAD.
David G. Cotter, MD, PhD: The Ideal Patient Candidate for Deuruxolitinib for Patients with Alopecia Areata
Send us Fan Mail
Dr. Cotter discusses providing rapid hair regrowth in patients with alopecia areata.
David G. Cotter, MD, PhD: Utilizing the 31-gene Expression Profile Test in Patients with Melanoma
Send us Fan Mail
Dr. Cotter discusses results of an expert consensus panel of the 31-gene expression profile test for patients with Melanoma.
David G. Cotter, MD, PhD: Providing Regrowth of Hair in Patients with Alopecia Areata
Send us Fan Mail
Dr. Cotter discusses providing effective treatment for patients with alopecia areata Â
James Del Rosso, DO: JCAD September 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the September 2025 issue of JCAD.
James Del Rosso, DO: JCAD August 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2025 issue of JCAD.
JCAD Dialogues and Reviews: Updates in Photoprotection and Recent Indication Expansions in Psoriasis and Rosacea
Send us Fan Mail
Dr. Del Rosso discusses advancements in photoprotection formulations, as well as recent FDA approvals that have expanded treatment options for rosacea and psoriasis.
James Del Rosso, DO: JCAD June 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2025 issue of JCAD.
Extended-cut Podcast— Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis
Send us Fan Mail
In this extended cut from JCAD’s recent Journal Review video series, Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: Mechanisms of Dupilumab-associated Arthralgia in Patients with Atopic Dermatitis
Drs. Issa and Bunick dive into the possible mechanistic explanations behind arthralgia associated with dupilumab, which was detailed in a case series by Drs. Issa and Bunick and their colleagues in the May issue of The Journal of Clinical and Aesthetic Dermatology.
Naiem Issa, MD, PhD, and Christopher Bunick, MD, PhD: JAK Inhibitors Reducing Dupilumab-associated Arthralgia in Patients with AD
James Del Rosso, DO: JCAD May 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2025 issue of JCAD.
James Del Rosso, DO: JCAD April 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the April 2025 issue of JCAD.
James Del Rosso, DO: JCAD February 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the February 2025 issue of JCAD.
JCAD Dialogues and Reviews: Highlighting a Vitiligo Roundtable Discussion in JCAD
Send us Fan Mail
Dr. James Del Rosso discusses a recent supplement that reviews insights about the challenges faced by both patients and clinicians in managing vitiligo.
JCAD Dialogues and Reviews: Considerations for Antibiotic Adverse Events
Send us Fan Mail
Dr. Del Rosso discusses potential adverse events that can occur when treating patients with trimethoprim-sulfamethoxazole.
James Del Rosso, DO: Discussion of Recent Vitiligo Supplement in JCAD
Dr. Del Rosso reviews a recent JCAD supplement titled “Vitiligo Exchange: An Expert Panel Discussion of Two Clinical Cases."
James Del Rosso, DO: JCAD January 2025 Issue Highlights
Send us Fan Mail
Dr. Del Rosso, Clinical Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the January 2025 issue of JCAD.
James Del Rosso, DO: Dermatology Year in Review 2024
Send us Fan Mail
Dr. Del Rosso reviews some of the most impactful research developments and drug approvals seen by the dermatology world in 2024.
JCAD Dialogues and Reviews: Spotlight on a Newly Approved Treatment for Rosacea
Send us Fan Mail
Dr. Del Rosso discusses warning signs of serious adverse events related to trimethoprim-sulfamethoxazole prescribed to patients with acne.
James Song, MD: Live from Elevate-Derm West—Why Older Immunosuppressant Agents are Still Relevant in 2024
Send us Fan Mail
Dr. Song provides helpful clinical tips for treating patients with methotrexate.Â
James Song, MD: Live from Elevate-Derm West—New Topical and Systemic Agents for Atopic Dermatitis
Send us Fan Mail
Dr. Song provides an extensive overview of what’s new and emerging in atopic dermatitis treatment.
